Potassium iodide (KI) prophylaxis — the thyroid-blocking agent administered within 4 hours of radioactive iodine exposure preventing isotope uptake and reducing thyroid cancer risk by 90%+ — represents the fastest-growing application segment in the iodine deficiency drug market, with the Iodine Deficiency Drug Market reflecting KI emergency stockpiling as the geopolitical risk...